Buraco macular

Buraco macular


Michel Eid Farah,
Carlos Augusto Moreira Jr.,
Marcos P. Ávila


Arquivos Brasileiros de Oftalmologia

versão impressa ISSN 0004-2749versão On-line ISSN 1678-2925

Arq. Bras. Oftalmol. vol.61 no.1 São Paulo fev. 1998



1 Avila MP, Jalkh AE, Murakamik, Trempe CL, Schepens CL. Biomicroscopic study of the vitreous in macular breaks. Ophthalmology 1983;90:1277-83.
2 Barrie T. Macular holes. Br J Ophthalmol, 1995;79:511-2.
3 De Bustros S. Vitrectomy for prevention of macular holes. results of a randomized multicenter clinical trial. vitrectomy for prevention of macular hole study group. Ophthalmology 1994;101:1055-9.
4 Duker JS, Wendel R, Patel AC, Puliafito CA. Late re-opering of macular holes after initially successful treatment with vitreous surgery. Ophthalmology 1994; 101:1373-8.
5 Farah ME, Oshima A, Lima ALH. Desaparecimento do buraco macular associado ao desenvolvimento de membrana epiretiniana. Arq Bras Oftal 1993; 56:243-6.
6 Freeman WR. Vitrectomy surgery for full-thickness macular holes. Am J Ophthalmol 1993;116:233-5.
7 Gass JDM. Stereoscopic atlas of macular diseases: diagnosis and treatment, 2nd ed., St. Louis: The C.V. Mosby, 1997;334.
8 Madreperla AS, Geiger GL, Funata M, De La Cruz Z, Green WR. Clinicopathologic correlation of a macular hole treated by cortical vitreous peeling and gas tamponade. Ophthalmology, 1994;101:682-6.
9 Park SS, Marcus DM, Duker JS, Pesavento RD, Topping TM, Frederick AR. Jr, D'amico DJ. Posterior segment complications after vitrectomy for macular hole. Ophthalmology 1995;102:775-81.
10 Ruby AJ, Williams DF, Grand MG, Thomas MA, Meredith TA, Boniuk I, Olk RJ. Pars plana vitrectomy for treatment of stage 2 macular holes. Arch Ophthalmol 1994; 112:359-64.
11 Ryan EA, Lee S, Chern S. Use of intravitreal autologous blood to identify posterior cortical vitreous in macular hole surgery. Arch Ophthalmol 1995; 113:822-3.
12 Thompson JT, Glaser BM, Sjaarda RN, Murphy RP, Hanham A. Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2. Ophthalmology 1994;101:1195-200.
13 Thompson JT, Hiner CJ, Glaser BM, Gordon AJ, Murphy RP, Sjaarda RN. Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2. J Ophthalmol 1994; 117:291-301.
14 West S. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol 1995;1119:819.